Genfit SA announced that strong commercial performance of Iqirvo® (licensed to Ipsen) in its first full year on the primary biliary cholangitis $(PBC)$ market has triggered a US$20 million milestone payment ahead of schedule. Ipsen reported US$88 million in Iqirvo® net sales for the fourth quarter of 2025, bringing total 2025 sales to US$208 million and surpassing the US$200 million threshold. This commercial milestone also enabled GENFIT to receive an additional €30 million tranche under its royalty-financing agreement with HCRx. GENFIT also reported progress in its pipeline, including full enrollment of a new dose-escalation cohort in its GNS561 Phase 1b cholangiocarcinoma study, with no dose-limiting toxicities reported at the 21-day timepoint. Phase 1b data readout and recommended Phase 2 doses are expected in the first half of 2026. GENFIT plans to publish its fourth quarter 2025 revenue and cash position on February 26, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfit SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001164536-en) on February 12, 2026, and is solely responsible for the information contained therein.